A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HRE2-positive primary breast cancer

  • Harris, Marion (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date28/02/19 → 27/02/24